mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern.

Haomeng WangZhao ChenZhenghua WangJin LiZhihong YanJinbo YuanAiru ZhuLan ChenYe LiuChenlong HuAli ZhuGuowei LiYuehu LiJie DengLiqiao MaXiuwen SuiWei MiaoJunqiang LiXiuyu ZhengJinhua PiaoYanfeng YaoJuhong RaoChao ShanZhi-Ming YuanJincun ZhaoTao Zhu

Published in: Emerging microbes & infections (2022)

In order to overcome the pandemic of COVID-19, messenger RNA (mRNA)-based vaccine has been extensively researched as a rapid and versatile strategy. Herein, we described the immunogenicity of mRNA-based vaccines for Beta and the most recent Omicron variants. The homologous mRNA-Beta and mRNA-Omicron and heterologous Ad5-nCoV plus mRNA vaccine exhibited high-level cross-reactive neutralization for Beta, original, Delta, and Omicron variants. It indicated that the COVID-19 mRNA vaccines have great potential in the clinical use against different SARS-CoV-2 variants.

Keyphrases

sars cov
coronavirus disease
binding protein
copy number
respiratory syndrome coronavirus
multidrug resistant
dna methylation
dna repair
saccharomyces cerevisiae